• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Officer Goldshleger Ilya

    2/27/25 8:05:28 PM ET
    $RXST
    Ophthalmic Goods
    Health Care
    Get the next $RXST alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Goldshleger Ilya

    (Last) (First) (Middle)
    C/O RXSIGHT, INC.
    100 COLUMBIA

    (Street)
    ALISO VIEJO CA 92656

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    RxSight, Inc. [ RXST ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director 10% Owner
    X Officer (give title below) Other (specify below)
    See remarks
    3. Date of Earliest Transaction (Month/Day/Year)
    02/27/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Stock Option (right to buy) $28.21 02/27/2025 A 125,000 (1) 02/26/2035 Common Stock 125,000 $0.00 125,000 D
    Explanation of Responses:
    1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through each applicable date, one forty-eighth (1/48th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean February 27, 2025.
    Remarks:
    Co-President and Chief Operating Officer
    /s/ Shelley Thunen, as Attorney-in-Fact 02/27/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $RXST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RXST

    DatePrice TargetRatingAnalyst
    5/19/2025$25.00Equal Weight → Overweight
    Wells Fargo
    4/15/2025$18.00Neutral
    Piper Sandler
    4/9/2025$16.00Buy → Neutral
    UBS
    4/4/2025$40.00 → $17.00Overweight → Underweight
    Analyst
    4/3/2025$36.00 → $22.00Buy → Underperform
    BofA Securities
    12/20/2024$65.00 → $40.00Buy → Hold
    Stifel
    12/11/2024$56.00 → $42.00Overweight → Equal Weight
    Wells Fargo
    12/6/2024$52.00Buy
    UBS
    More analyst ratings

    $RXST
    SEC Filings

    See more
    • SEC Form SD filed by RxSight Inc.

      SD - RxSight, Inc. (0001111485) (Filer)

      5/20/25 4:30:10 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 10-Q filed by RxSight Inc.

      10-Q - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:15:25 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - RxSight, Inc. (0001111485) (Filer)

      5/7/25 4:10:09 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum

      ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Stifel Virtual Ophthalmology Forum. RxSight's management is scheduled to participate in a fireside chat on Tuesday, May 27, 2025, at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providin

      5/20/25 4:10:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Present at the Bank of America Healthcare Conference

      ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference in Las Vegas. RxSight's management is scheduled to present on Wednesday, May 14, 2025, at 3:40 p.m. Pacific Time / 6:40 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized visio

      4/30/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • RxSight upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded RxSight from Equal Weight to Overweight and set a new price target of $25.00

      5/19/25 8:47:30 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Piper Sandler initiated coverage on RxSight with a new price target

      Piper Sandler initiated coverage of RxSight with a rating of Neutral and set a new price target of $18.00

      4/15/25 9:02:26 AM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight downgraded by UBS with a new price target

      UBS downgraded RxSight from Buy to Neutral and set a new price target of $16.00

      4/9/25 8:36:59 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Leadership Updates

    Live Leadership Updates

    See more
    • Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board

      Shareholders approved all agenda items and proposals of the Board of DirectorsRobert K. Warner, M.B.A. and Arshad M. Khanani, M.D., M.A., FASRS elected as members of the Board of DirectorsBaruch D. Kuppermann, M.D., Ph.D. and Frank G. Holz, M.D., Ph.D. appointed as members of the Scientific Advisory BoardOculis established a CHF 50 million flexible loan facility with funds and accounts managed by BlackRock ZUG, Switzerland, May 30, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (NASDAQ:OCS, XICE: OCS))) ("Oculis" or the "Company"), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced the results from its 2024 Annual General Meeting

      5/30/24 4:00:00 AM ET
      $ALC
      $NARI
      $OCS
      $RXST
      Ophthalmic Goods
      Health Care
      Medical/Dental Instruments
      Biotechnology: Pharmaceutical Preparations
    • RxSight, Inc. Appoints Dr. Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors

      ALISO VIEJO, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced the appointment of Tamara R. Fountain, M.D. and Shweta Singh Maniar to its Board of Directors. "We are very excited to continue to strengthen the RxSight Board of Directors with the additions of Dr. Fountain and Ms. Maniar. Their diverse healthcare leadership experience will support the strategic advancement of the company through its next chapter of growth," said J. Andy Corley, Chair of the Board of Directors. "We look forward to their respective contributions as the RxSight® Lig

      1/4/22 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Financials

    Live finance-specific insights

    See more
    • RxSight, Inc. Reports First Quarter 2025 Financial Results

      ALISO VIEJO, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended March 31, 2025. Key Quarterly Highlights Reported first quarter 2025 revenue of $37.9 million, an increase of 28% compared to the first quarter of 2024, reflecting: The sale of 27,579 Light Adjustable Lenses (LAL®/LAL+®), representing a 36% increase in procedure volume compared to the first quarter of 2024;The sale of 73 Light Delivery Devices (LDD™s), bringing the installed base to 1,044 LDDs as of M

      5/7/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025

      ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations web

      4/23/25 4:05:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance

      ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced select preliminary revenue results for the first quarter 2025 and revised full-year 2025 guidance. The Company will host a conference call on Thursday, April 3, 2025, at 8:00 a.m. Eastern Time. Preliminary First Quarter 2025 Results Preliminary first quarter 2025 revenue is expected to be approximately $37.9 million, representing growth of 28% compared to the prior year period, and a decrease of 6% compared to the fourth quarter of 2024, driven by: The sale

      4/2/25 8:00:00 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/14/24 5:46:12 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 4:50:57 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Amendment: SEC Form SC 13G/A filed by RxSight Inc.

      SC 13G/A - RxSight, Inc. (0001111485) (Subject)

      11/12/24 9:40:27 AM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Corley Jesse Anderson bought $100,004 worth of shares (3,210 units at $31.15) (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      1/17/25 7:08:42 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Corley Jesse Anderson bought $1,014,570 worth of shares (22,476 units at $45.14), increasing direct ownership by 18% to 38,438 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      11/14/24 7:14:14 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Tammenoms Bakker Juliet bought $305,456 worth of shares (5,000 units at $61.09), increasing direct ownership by 17% to 34,840 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      5/21/24 4:11:17 PM ET
      $RXST
      Ophthalmic Goods
      Health Care

    $RXST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Thunen Shelley B exercised 7,792 shares at a strike of $4.34, increasing direct ownership by 25% to 38,354 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      4/15/25 8:57:36 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • Director Fountain Tamara sold $180,002 worth of shares (7,000 units at $25.71), decreasing direct ownership by 22% to 24,793 units (SEC Form 4)

      4 - RxSight, Inc. (0001111485) (Issuer)

      3/13/25 4:46:51 PM ET
      $RXST
      Ophthalmic Goods
      Health Care
    • SEC Form 4 filed by Officer Weinberg Eric

      4 - RxSight, Inc. (0001111485) (Issuer)

      2/27/25 8:06:48 PM ET
      $RXST
      Ophthalmic Goods
      Health Care